Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

E Monahan

Showing results (111-120 of 128) with videos related to

Pageof 13
Sort By:
Transfusion|September 25, 2012
Evidence for the transmission of parvovirus B19 in patients with bleeding disorders treated with plasma-derived factor concentrates in the era of nucleic acid test screeningJ Michael Soucie, Christine De Staercke, Paul E Monahan, et al.
Cancer Research|June 24, 2011
A drug resistance screen using a selective MET inhibitor reveals a spectrum of mutations that partially overlap with activating mutations found in cancer patientsRalph Tiedt, Elisa Degenkolbe, Pascal Furet, et al.
Journal of Thrombosis and Haemostasis : JTH|September 19, 2015
Inhibitor recurrence after immune tolerance induction: a multicenter retrospective cohort studyA Antun, P E Monahan, M J Manco-Johnson, et al.
Molecular Therapy : the Journal of the American Society of Gene Therapy|November 10, 2011
Phase 1 gene therapy for Duchenne muscular dystrophy using a translational optimized AAV vectorDawn E Bowles, Scott W J McPhee, Chengwen Li, et al.
Research and Practice in Thrombosis and Haemostasis|February 27, 2026
Etranacogene dezaparvovec in people with hemophilia B with preexisting adeno-associated virus 5 neutralizing antibodies: 4-year subgroup results from the HOPE-B trialRobert Klamroth, Paul E Monahan, Paul Van der Valk, et al.
Cancer Discovery|July 12, 2013
An F876L mutation in androgen receptor confers genetic and phenotypic resistance to MDV3100 (enzalutamide)Manav Korpal, Joshua M Korn, Xueliang Gao, et al.
Human Gene Therapy|November 25, 2014
Employing a gain-of-function factor IX variant R338L to advance the efficacy and safety of hemophilia B human gene therapy: preclinical evaluation supporting an ongoing adeno-associated virus clinical trialPaul E Monahan, Junjiang Sun, Tong Gui, et al.
Nature Communications|October 29, 2021
Improvement of a synthetic live bacterial therapeutic for phenylketonuria with biosensor-enabled enzyme engineeringKristin J Adolfsen, Isolde Callihan, Catherine E Monahan, et al.
Blood|October 17, 2020
BAX 335 hemophilia B gene therapy clinical trial results: potential impact of CpG sequences on gene expressionBarbara A Konkle, Christopher E Walsh, Miguel A Escobar, et al.
The New England Journal of Medicine|November 17, 2021
Multiyear Factor VIII Expression after AAV Gene Transfer for Hemophilia ALindsey A George, Paul E Monahan, M Elaine Eyster, et al.
Pageof 13

Showing results (111-120 of 128) with videos related to

Sort By:
Pageof 13
Transfusion|September 25, 2012
Evidence for the transmission of parvovirus B19 in patients with bleeding disorders treated with plasma-derived factor concentrates in the era of nucleic acid test screeningJ Michael Soucie, Christine De Staercke, Paul E Monahan, et al.
Cancer Research|June 24, 2011
A drug resistance screen using a selective MET inhibitor reveals a spectrum of mutations that partially overlap with activating mutations found in cancer patientsRalph Tiedt, Elisa Degenkolbe, Pascal Furet, et al.
Journal of Thrombosis and Haemostasis : JTH|September 19, 2015
Inhibitor recurrence after immune tolerance induction: a multicenter retrospective cohort studyA Antun, P E Monahan, M J Manco-Johnson, et al.
Molecular Therapy : the Journal of the American Society of Gene Therapy|November 10, 2011
Phase 1 gene therapy for Duchenne muscular dystrophy using a translational optimized AAV vectorDawn E Bowles, Scott W J McPhee, Chengwen Li, et al.
Research and Practice in Thrombosis and Haemostasis|February 27, 2026
Etranacogene dezaparvovec in people with hemophilia B with preexisting adeno-associated virus 5 neutralizing antibodies: 4-year subgroup results from the HOPE-B trialRobert Klamroth, Paul E Monahan, Paul Van der Valk, et al.
Cancer Discovery|July 12, 2013
An F876L mutation in androgen receptor confers genetic and phenotypic resistance to MDV3100 (enzalutamide)Manav Korpal, Joshua M Korn, Xueliang Gao, et al.
Human Gene Therapy|November 25, 2014
Employing a gain-of-function factor IX variant R338L to advance the efficacy and safety of hemophilia B human gene therapy: preclinical evaluation supporting an ongoing adeno-associated virus clinical trialPaul E Monahan, Junjiang Sun, Tong Gui, et al.
Nature Communications|October 29, 2021
Improvement of a synthetic live bacterial therapeutic for phenylketonuria with biosensor-enabled enzyme engineeringKristin J Adolfsen, Isolde Callihan, Catherine E Monahan, et al.
Blood|October 17, 2020
BAX 335 hemophilia B gene therapy clinical trial results: potential impact of CpG sequences on gene expressionBarbara A Konkle, Christopher E Walsh, Miguel A Escobar, et al.
The New England Journal of Medicine|November 17, 2021
Multiyear Factor VIII Expression after AAV Gene Transfer for Hemophilia ALindsey A George, Paul E Monahan, M Elaine Eyster, et al.
Pageof 13